QCM
KROS icon

Quantinno Capital Management’s Keros Therapeutics KROS Stock Holding History

Quantinno Capital Management’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$262K Buy
23,759
+2,639
+12% +$40.8K ﹤0.01% 3103
2025
Q4 		$430K Sell
21,120
-11
-0.1% -$193 ﹤0.01% 2567
2025
Q3 		$334K Buy
+21,131
New +$312K ﹤0.01% 2370

Other funds holding KROS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return

Quantinno Capital Management's KROS Position: Q1 2026 in Review

Quantinno Capital Management increased its Keros Therapeutics (KROS) stake by 12% in Q1 2026, buying an estimated $40.8K and bringing the position to 23,759 shares worth $262K. The position accounts for ﹤0.01% of the portfolio, ranked #3103.

Quantinno Capital Management first reported a position in KROS in Q3 2025 and has held it in 3 quarters since. The position peaked at $430K in Q4 2025. 151 funds tracked by Wall St. Rank hold KROS as of Q1 2026.

  • Quantinno Capital Management held 23,759 shares of Keros Therapeutics worth $262K as of Q1 2026.
  • Quantinno Capital Management bought 2,639 Keros Therapeutics shares in Q1 2026, an estimated $40.8K.
  • Keros Therapeutics made up ﹤0.01% of Quantinno Capital Management's portfolio in Q1 2026, its #3103 holding.
  • Quantinno Capital Management first reported a position in Keros Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • Quantinno Capital Management's Keros Therapeutics position peaked at $430K in Q4 2025.
  • 151 funds tracked by Wall St. Rank held Keros Therapeutics as of Q1 2026.

Based on Quantinno Capital Management's 13F filing for Q1 2026, filed 15 May 2026.